Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics develops RNA medicines intended to restore protein expression, using its TANGO approach and antisense oligonucleotides for diseases caused by insufficient gene output. Its lead investigational medicine, zorevunersen, is in development for Dravet syndrome, with earlier work directed at rare genetic neurodevelopmental and other haploinsufficiency diseases.
Company news commonly covers zorevunersen clinical data, EMPEROR study updates, financial results, capital resources, collaboration activity, board and governance changes, equity inducement grants under Nasdaq rules, and healthcare conference presentations.
Stoke Therapeutics (Nasdaq: STOK) announced that CEO Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 11:00 a.m. ET. A live webcast and archived replay will be available in the Investors & News section of Stoke’s website.
The company is developing its lead investigational antisense oligonucleotide, zorevunersen, a potential disease-modifying treatment for Dravet syndrome, currently in a Phase 3 study and partnered with Biogen (Nasdaq: BIIB) under a regional commercialization collaboration.
Stoke Therapeutics (Nasdaq: STOK) reported second quarter 2026 revenue of $9.3 million, down from $13.8 million a year earlier, and a net loss of $61.6 million, or $0.93 per share. For the first half of 2026, revenue was $15.6 million versus $172.4 million in 2025, with a net loss of $111.6 million compared to prior-year net income of $89.4 million.
As of June 30, 2026, Stoke held $354.3 million in cash, cash equivalents and marketable securities, supplemented by $65.7 million from a subsequent ATM sale, totaling about $420 million, which is expected to fund operations through a potential U.S. commercialization of zorevunersen in early 2028. Enrollment of 162 patients in the global Phase 3 EMPEROR study in Dravet syndrome is complete, with primary data expected in Q3 2027 to support a rolling U.S. NDA beginning Q1 2027. The Phase 1 OSPREY study of STK-002 in ADOA has completed dosing in the first cohort with no serious or severe safety events observed and a safety and efficacy readout anticipated in H1 2027.
Stoke Therapeutics (Nasdaq: STOK) will host a webcast and conference call on Monday, August 3, 2026, at 4:30 p.m. ET to provide second quarter 2026 business and financial updates. The event will stream via the Investors & News section of Stoke’s website, with research analysts registering separately for Q&A dial-in details and other participants joining a listen-only webcast. An archived replay will be accessible for at least 90 days. Stoke is developing the investigational antisense oligonucleotide zorevunersen for Dravet syndrome and has a strategic collaboration with Biogen (Nasdaq: BIIB) for its global commercialization rights.
Stoke Therapeutics (Nasdaq: STOK) granted inducement stock options under Nasdaq Listing Rule 5635(c)(4), effective July 15, 2026, to newly appointed Chief Scientific Officer Thomas McCauley and seven other new employees. McCauley received options to purchase 225,000 shares of common stock; the seven additional hires received options for an aggregate 83,070 shares.
According to Stoke Therapeutics, all options carry a $29.91 exercise price, equal to the July 15, 2026 closing price, have a 10-year term, and vest over four years (25% after one year, then monthly over 36 months), subject to continued employment and the 2023 Inducement Plan terms.
Stoke Therapeutics (Nasdaq: STOK) announced the appointment of Thomas McCauley, Ph.D., as Chief Scientific Officer. McCauley brings more than 25 years of experience building R&D organizations, advancing novel technology platforms, and translating early research into approved medicines for severe and rare diseases, including genetic medicines at Shire.
He will lead Stoke’s scientific strategy and leverage its proprietary RNA medicines platform to expand and advance the pipeline, including the lead investigational medicine zorevunersen, which is in late-stage development as a potential first-in-class, disease-modifying treatment for Dravet syndrome. McCauley previously held senior scientific leadership roles at Neptune Bio, Omega Therapeutics, Macrolide Pharmaceuticals, Translate Bio, and others.
Stoke Therapeutics (Nasdaq:BIIB) completed enrollment of 162 patients in the global Phase 3 EMPEROR study of investigational Dravet syndrome therapy zorevunersen. About 50 patients have reached the 28-week primary endpoint time point and no patients have discontinued treatment.
Stoke plans to begin a rolling U.S. NDA submission in Q1 2027, with Phase 3 data expected in Q3 2027 to support completion of the NDA in the second half of 2027 and a potential U.S. launch by early 2028.
Stoke Therapeutics (Nasdaq: STOK) granted stock options as inducement awards to nine new employees under Nasdaq Listing Rule 5635(c)(4), effective June 15, 2026.
The options cover an aggregate 103,020 shares at an exercise price of $30.00 per share, vest over four years, and have a 10-year term under the 2023 Inducement Plan.
Stoke Therapeutics (Nasdaq: STOK) will present at two investor conferences in June 2026. CEO Ian F. Smith and Chief Patient Officer Jason Hoitt will speak at the Jefferies Global Healthcare Conference on June 4 in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8 in Miami.
Live webcasts and archived replays will be available in the Investors & News section of Stoke Therapeutics’ website.
Stoke Therapeutics (Nasdaq: STOK) granted stock options to eight new employees as material inducement awards under Nasdaq Listing Rule 5635(c)(4), effective May 15, 2026. The grants cover 106,200 shares at an exercise price of $30.08 per share.
Options vest over four years and have a 10-year term.
Stoke Therapeutics (Nasdaq: STOK) reported Q1 2026 results and new 4-year Phase 1/2a OLE data for zorevunersen in Dravet syndrome. The OLE shows statistically significant improvements in cognition and behavior at 1–4 years and durable reductions in major motor seizures through four years.
As of March 31, 2026, cash, cash equivalents and marketable securities totaled $411.0 million, including $80.7 million from selective ATM sales, expected to fund operations into 2028. Phase 3 EMPEROR enrollment is nearing completion (~130 randomized of ~150; final randomization expected June 2026) to support a mid-2027 data readout and a planned rolling U.S. NDA starting in Q1 2027.